A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

Summary

A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.

Timeline

Start

2026-05-11

Primary completion

2027-03

Completion

2027-06

Drugs

Indications